Literature DB >> 17115967

Guidelines for the prevention, detection and management of people with chronic heart failure in Australia 2006.

Henry Krum1, Michael V Jelinek, Simon Stewart, Andrew Sindone, John J Atherton, Anna L Hawkes.   

Abstract

Chronic heart failure (CHF) is found in 1.5%-2.0% of Australians. Considered rare in people aged less than 45 years, its prevalence increases to over 10% in people aged >/= 65 years. CHF is one of the most common reasons for hospital admission and general practitioner consultation in the elderly (>/= 70 years). Common causes of CHF are ischaemic heart disease (present in > 50% of new cases), hypertension (about two-thirds of cases) and idiopathic dilated cardiomyopathy (around 5%-10% of cases). Diagnosis is based on clinical features, chest x-ray and objective measurement of ventricular function (eg, echocardiography). Plasma levels of B-type natriuretic peptide (BNP) may have a role in diagnosis, primarily as a test for exclusion. Diagnosis may be strengthened by a beneficial clinical response to treatment(s) directed towards amelioration of symptoms. Management involves prevention, early detection, amelioration of disease progression, relief of symptoms, minimisation of exacerbations, and prolongation of survival.

Entities:  

Mesh:

Year:  2006        PMID: 17115967     DOI: 10.5694/j.1326-5377.2006.tb00690.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  20 in total

1.  Evidence-based approach to exercise prescription in chronic heart failure.

Authors:  Steve E Selig; David L Hare
Journal:  Br J Sports Med       Date:  2007-02-08       Impact factor: 13.800

2.  Co-morbidity and potential treatment conflicts in elderly heart failure patients: a retrospective, cross-sectional study of administrative claims data.

Authors:  Gillian E Caughey; Elizabeth E Roughead; Sepehr Shakib; Agnes I Vitry; Andrew L Gilbert
Journal:  Drugs Aging       Date:  2011-07-01       Impact factor: 3.923

3.  Integrating PoCT into Clinical Care.

Authors:  Philip Tideman; Paul Simpson; Rosy Tirimacco
Journal:  Clin Biochem Rev       Date:  2010-08

4.  A Computer Simulation of Community Pharmacy Practice for Educational Use.

Authors:  Ivan Bindoff; Tristan Ling; Luke Bereznicki; Juanita Westbury; Leanne Chalmers; Gregory Peterson; Robert Ollington
Journal:  Am J Pharm Educ       Date:  2014-11-15       Impact factor: 2.047

5.  Influence of cerebral blood flow on central sleep apnea at high altitude.

Authors:  Keith R Burgess; Samuel J E Lucas; Kelly Shepherd; Andrew Dawson; Marianne Swart; Kate N Thomas; Rebekah A I Lucas; Joseph Donnelly; Karen C Peebles; Rishi Basnyat; Philip N Ainslie
Journal:  Sleep       Date:  2014-10-01       Impact factor: 5.849

6.  Predictors of uncontrolled hypertension in the Stroke Belt.

Authors:  Gaurav J Dave; Daniel L Bibeau; Mark R Schulz; Robert E Aronson; Louise L Ivanov; Adina Black; Lapronda Spann
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-05-09       Impact factor: 3.738

7.  A self-controlled case series to assess the effectiveness of beta blockers for heart failure in reducing hospitalisations in the elderly.

Authors:  Emmae N Ramsay; Elizabeth E Roughead; Ben Ewald; Nicole L Pratt; Philip Ryan
Journal:  BMC Med Res Methodol       Date:  2011-07-18       Impact factor: 4.615

8.  Use, tolerability and compliance of spironolactone in the treatment of heart failure.

Authors:  Jean Lachaine; Catherine Beauchemin; Elodie Ramos
Journal:  BMC Clin Pharmacol       Date:  2011-05-20

9.  NT-ProBNP levels in saliva and its clinical relevance to heart failure.

Authors:  Jared Yong Yang Foo; Yunxia Wan; Karam Kostner; Alicia Arivalagan; John Atherton; Justin Cooper-White; Goce Dimeski; Chamindie Punyadeera
Journal:  PLoS One       Date:  2012-10-31       Impact factor: 3.240

10.  Development of an economic model to assess the cost-effectiveness of hawthorn extract as an adjunct treatment for heart failure in Australia.

Authors:  Emily Ford; Jon Adams; Nicholas Graves
Journal:  BMJ Open       Date:  2012-09-01       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.